Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims

1. (original) Use of a protective oligodeoxyribonucleotide for the manufacture of a medicament for the treatment of a patient undergoing treatment with an immunosuppressant.

2. (original) Use of a protective oligodeoxyribonucleotide for the manufacture of a medicament for protecting epithelial and/or endothelial cells from the effects of an immunosuppressant.

3. (original) Use of a protective oligodeoxyribonucleotide for the manufacture of a medicament for protecting epithelial and/or endothelial cells from apoptosis and/or activation induced by the administration of an immunosuppressant.

4. (currently amended) Use according to ~~claims 1—3~~ claim 1 wherein the immunosuppressant is a nucleoside.

5. (currently amended) Use according to ~~claims 1—3~~ claim 1 wherein the immunosuppressant is selected from the ~~groups~~ group comprising fludarabine, cyclophosphamide, BCNU, melphalan.

6. (cancelled)

7. (currently amended) Use according to ~~claims 1—3~~ claim 1 wherein the protective oligodeoxyribonucleotide is defibrotide.

8. (currently amended) Use according to ~~claims 1—7~~ claim 1 wherein the step of administering the protective oligodeoxyribonucleotide occurs ~~concomitantly,~~ simultaneously~~,~~ ~~after or before~~ with the administration of the immunosuppressant to the patient.

9. (currently amended) Use according to claim ~~8~~ 1 wherein the step of administering the protective oligodeoxyribonucleotide occurs after that of administering the immunosuppressant

to the patient.

10. (currently amended) Use according to claim 9 wherein the time delay between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks~~, preferably from about two days to about seven days~~.

11. (currently amended) Use according to claim ~~8~~ 1 wherein the step of administering the protective oligodeoxyribonucleotide occurs before that of administering the immunosuppressant to the patient.

12. (currently amended) Use according to claim 11 wherein the time difference between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks~~, preferably from about two hours to tow days~~.

13. (currently amended) Use according to ~~claims 1 12~~ claim 7 wherein the dose of the defibrotide administered is chosen so as to reach a blood level from about 100 μg/mL to about 0.1 μg/~~mgL~~mL~~, preferably from about 10 μg/ml to about 100 μg/mL~~.

14. (original) Use according to claim 13 wherein the dose of defibrotide administered is chosen so as to reach a blood level of about 10 μg/mL.

15. (currently amended) Use according ~~to claims 1 14~~ claim 7 wherein the dose of defibrotide administered is from about 100 mg/kg body weight of the patient to about 0.01 mg/kg body weight~~, preferably from about 20 mg/kg weight of the patient to about 0.1 mg/kg body weight~~.

16. (currently amended) Use according to claim 15 wherein the dose of defibrotide administered is from about 15 mg/kg body weight of the patient to about 1mg/kg body weight~~, preferably about 12 mg/kg body weight of the patient~~.

17. (currently amended) Use according to claim 3 ~~any one of the preceding claims~~ wherein the activation includes enhanced expression of ICAM-1.

18. (currently amended) Use according to claim 1 ~~any one of the preceding claims~~ wherein the treatment with an immunosuppressant occurs during stem cell translation.

19. (original) Use according to claim 18 wherein the stem cell transplantation is allogeneic stem cell transplantation.

20. (original) A pharmaceutical composition containing a therapeutically effective dose of an immunosuppressant and of a protective oligodeoxyribonucleotide.

21. (original) A pharmaceutical composition according to claim 20 constituted by two different separately administrable formulations, one containing the immunosuppressant and the other the protective oligodeoxyribonucleotide.

22. (currently amended) A pharmaceutical composition according to claim 20 as a combined preparation for simultaneous~~, separate or sequential~~ use.

23. (currently amended) A pharmaceutical composition according to claim 20 ~~claims 20 – 22~~ wherein the immunosuppressant is a nucleoside.

24. (currently amended) A pharmaceutical composition according to claim 20 ~~claims 20-22~~ wherein the immunosuppressant is selected from the ~~groups~~ group comprising fludarabine, cyclophosphamide, BCNU, melphalan.

25. (cancelled)

26. (currently amended) A pharmaceutical composition according to claim 20 ~~20-22~~ wherein the protective oligodeoxyribonucleotide is defibrotide.

27. (currently amended) A pharmaceutical composition according to claim 20 ~~any one of the preceding claims~~ characterized by further containing customary excipients and/or adjuvants.

28. (currently amended) A pharmaceutical composition according to claim 20 ~~any one of the preceding claims~~ characterized in that it is intravenously inject able.

29. (new) Use according to claim 9 wherein the time delay between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about two days to about seven days.

30. (new) Use according to claim 11 wherein the time difference between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about two hours to about two days.

31. (new) Use according to claim 7 wherein the dose of the defibrotide administered is chosen so as to reach a blood level from about 10 μg/mL to about 100 μg/mL.

32. (new) Use according claim 7 wherein the dose of defibrotide administered is from about 20 mg/kg weight of the patient to about 0.1 mg/kg body weight.

33. (new) Use according claim 32 wherein the dose of defibrotide administered is about 12 mg/kg weight of the patient.

34. (new) A pharmaceutical composition according to claim 20 as a combined preparation for separate use.

35. (new) A pharmaceutical composition according to claim 20 as a combined preparation for sequential use.